

MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG

Alcon Presents Comprehensive Scientific Program With 59 Abstracts at ESCRS 2022

- **Vivity Registry Study continues to highlight reduced spectacle dependence and high patient satisfaction**
- **Additional abstracts on Alcon's leading products, part of the Alcon Vision Suite, show efficiency benefits in diagnostics and phacoemulsification**
- **HORIZON Clinical Study reveals sustained safety and efficacy of the Hydrus Microstent**

GENEVA, September 14, 2022 – Alcon, the global leader in eye care dedicated to helping people see brilliantly, will present extensive data during the 2022 Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Milan, Italy, September 16-20. The official program will feature 59 abstracts, with more than 30 focused on Alcon's intraocular lens (IOL) technologies, notably AcrySof® IQ Vivity™. Additional data will be presented on Argos® Biometer and ACTIVE SENTRY® Handpiece, which are part of the Alcon Vision Suite – Alcon's leading products, digital solutions and services ecosystem. Data on one of Alcon's latest additions, the Hydrus® Microstent, will also be presented.

"Alcon is proud to have such a significant scientific presence at the ESCRS Congress in Milan that spans across our portfolio," said Michel Letort, EMEA Head of Medical Affairs at Alcon. "The data presented continues to demonstrate that the efficiency of our equipment and implantables support surgeons in delivering brilliant patient outcomes."

Reduced spectacle dependence and high patient satisfaction with AcrySof® IQ Vivity™ IOL continue with the first and only presbyopia-correcting IOL with wavefront-shaping technology and a clinically proven, exceptionally low rate of visual disturbances.¹⁻³ Key data continues to demonstrate that Vivity™ delivers an extended range of vision while maintaining a visual disturbance profile comparable to the best-in-class AcrySof® IQ monofocal.¹⁻²

Second interim analysis of the Vivity™ Registry Study, a real-world, multi-country, ambispective, non-comparative, open-label, non-interventional study/registry conducted in Europe, New Zealand and Australia, demonstrated:

- 92.9% and 88.7% of patients reported "never" or "rarely" using eyeglasses to see at distance and intermediate in bright light;^{*†}
- Uncorrected binocular vision was of 20/20 at distance, 20/25 at intermediate and 20/32 at near;^{*}
- More than 91% of the patients did not report any visual disturbances, halos, glare or starbursts;^{*†}
- 91.4% of the patients were satisfied with their sight.^{*§}

Additional sub-group analyses per country, per site, as well as by comorbidities, in post-corneal refractive patients and mini-monovision will be presented at the scientific sessions during ESCRS congress in Milan.

Other key presentations on AcrySof® IQ Vivity™ IOL include:

- Clinical impact of residual astigmatism in patients with a novel presbyopia-correcting intraocular lens by Rementeria L, et al.
- Clinical performance of the extended range of vision intraocular lens Vivity™ in patients with previous corneal laser refractive surgery by Carreras H, et al.
- Comparison of near visual acuity using a non-diffractive extended depth-of-focus IOL with different target refractions by Mayer W, et al.
- Visual acuity and spectacle independence of patients implanted with three extended depth of focus IOLs or a monofocal one as the control by Del Pozo Lérída S, et al.
- Visual disturbances produced after the implantation of three extended-depth-of-focus intraocular lenses versus one monofocal lens by Guarro M, et al.

Several additional abstracts address elements of the Alcon Vision Suite offering surgeons enhanced efficiency and accuracy to help improve patient outcomes.⁴⁻⁸

In diagnostics, the Argos® Biometer⁹ demonstrated a lowest refractive prediction error versus comparable Optical coherence tomography and optical low coherence reflectometry biometers¹⁰ and higher acquisition rate in eyes with dense cataracts when compared to an optical biometer.¹¹⁻¹² The acquisition rate in the dense cataract population for Argos® was 89% compared to another biometer at 59% (p=0,0047).¹¹ Another study in eyes with dense cataracts shows that Argos® Biometer achieves 100% acquisition rate of the axial length compared to 66.66% for a different biometer.¹²

In addition, several investigators demonstrated that the built-in fluidics pressure sensor in the ACTIVE SENTRY® Handpiece¹³ improved phacoemulsification efficiency by reducing the amount of energy used during the procedures (CDE 6,2 vs 6,7; P=0.0001) and shortened their duration (total ultrasound time 48.0 vs 57.0; P<0.0001) compared to traditional phacoemulsifier-based sensors.¹⁴

Sustained safety and efficacy of the Hydrus® Microstent through 5-year follow-up of a cohort of patients enrolled in HORIZON Clinical Study. The longest, continuous follow-up of a minimally invasive glaucoma surgery (MIGS) device reveals significantly reduced medication use in the treated group compared to cataract surgery alone (66% vs 46%; p≤0.001), as well as a reduction in the frequency of further glaucoma surgeries.¹⁵

The full abstract book and details of Alcon's presence are [available here](#).

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Please refer to relevant product direction for use and operator manual for list of indications, contraindications and warnings.

References

1. AcrySof® IQ Vivity™ Extended Vision IOL Directions for Use.
2. Alcon Data on File, US Patent 9968440 B2, May 15, 2018.
3. A Prospective, Randomized, Controlled, Multi-Center Clinical Study of the ACRYSOFF® IQ Extended Depth of Focus (EDF) IOL.
4. Alcon Data on File, 2020.
5. Blaylock JF, Hall B. Astigmatic results of a diffractive trifocal toric IOL following intraoperative aberrometry guidance. *Clin Ophthalmol.* 2020;14:4373-4378. doi:10.2147/OPHTH.S285711.
6. Cionni RJ, Dimalanta R, Breen M, Hamilton C. A large retrospective database analysis comparing outcomes of intraoperative aberrometry with conventional preoperative planning. *J Cataract Refract Surg.* 2018;44(10):1230-1235. doi:10.1016/j.jcrs.2018.07.016.
7. Van Vliet EJ, Bredenhoff E, Sermeus W, Kop LM, Sol JCA, Harten WH. Exploring the relation between process design and efficiency in high-volume cataract pathways from a lean thinking perspective. *Int J Qual Health Care.* 2011;23(1):83-93. doi:10.1093/intqhc/mzq071.
8. Håkansson I, Lundström M, Stenevi U, Ehinger B. Data reliability and structure in the Swedish National Cataract Register. *Acta Ophthalmol Scand.* 2001;79(5):518-523. doi:10.1034/j.1600-0420.2001.790519.
9. ARGOS® Biometer User Manual 2019.
10. B Gjerdrum. Refractive Predictability of a Combined Optical Coherence Tomography (OCT) and Reflection Biometer. Free Poster. 16-20 Sept. ESCRS 2022 Milan.
11. B Von Jagow Axial length acquisition rates of ARGOS-Biometer and the IOL-Master 700-Biometer in eyes with dense cataract. Free Poster. 16-20 Sept. ESCRS 2022 Milan.
12. P Orts-Vila. Evaluation of SS-OCT and PCI Optical Biometry in Eyes With Dense Cataract. Free Poster. 16-20 Sept. ESCRS 2022 Milan.
13. Active Sentry® pressure sensing handpiece Directions for use.
14. A Brezin. Evaluation of a Phacoemulsification Handpiece With a Built-In Fluidics Pressure Sensor: The Sasca Multicenter Study (Study of Active Sentry In Cataract Surgery. Free Paper. 16-20 Sept. ESCRS 2022 Milan.
15. L Au. 5-Year Safety and Effectiveness of Phacoemulsification Combined With a Schlemm's Canal Microstent: Results From the Horizon Trial. Free Paper. 16-20 Sept. ESCRS 2022 Milan.

*Second interim analysis outcomes (757 subjects implanted bilaterally) from a multi-country, ambispective, non-comparative, open-label, non-interventional study (registry) conducted in Europe, New Zealand, and Australia with 3-6 months follow-up.

‡ Patients were asked, "In the past 7 days, how often did you need to wear eyeglasses to see?"

† Visual disturbances were evaluated in a non-prompted interview.

§ Subject satisfaction were evaluated with the Catquest 9SF Questionnaire. This refers to fairly/very satisfied.

Connect with us on



Media Relations

Cara Jones Faye

+ 41 79 93 3811

cara.jones_faye@alcon.com